NAD3: What Is It, What Does the Human Evidence Show?

Written by the Nuvirox Research Team

Short answer: NAD3 is an interesting early-stage ingredient with one published human trial showing lipid and cellular NAD+ ratio benefits — but the evidence base is thin, and it is categorically different from precursor supplements like NMN or NR. When people search "NAD3," they are sometimes looking for information about NMN or NAD+ supplements generally and have encountered the term in a product listing. NAD3 is a specific trademarked ingredient with its own mechanism, its own trial record, and its own honest limitations. Here is what the science actually says.

What is NAD3 exactly?

NAD3® is a multi-patent-pending nutraceutical ingredient developed by JUVN3 Holdings and distributed by Compound Solutions. Its formula contains three components: Wasabia japonica (wasabi) freeze-dried rhizome standardized for isothiocyanates, theacrine (a purine alkaloid found in certain teas), and a copper(I)-niacin chelate. The total dose used in the published human trial was 312 mg of this combined blend per day.

This is a fundamentally different approach than supplementing with NAD+ precursors. NMN and NR work by providing raw material that cells convert to NAD+ through the salvage biosynthesis pathway. NAD3, by contrast, is hypothesized to work by upregulating the enzymes that boost NAD+ synthesis from its precursors — while simultaneously suppressing CD38 and other NAD+-consuming proteins that deplete cellular NAD+. In theory, this could amplify net intracellular NAD+ status without requiring exogenous precursor load. The manufacturer has described NAD3 as a potential companion ingredient to NMN or NR rather than a standalone replacement. For context on how precursor supplementation works, see our article on Nicotinamide Riboside: What It Does, What the Trials Show.

Conceptual comparison of precursor supplementation (NMN/NR) versus the proposed mechanism of NAD3. Illustration is mechanistically simplified and not drawn to biological scale.

What is theacrine and why is it in NAD3?

Theacrine is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica (Chinese tea) and Herrania and Theocrama species. It has been studied primarily as an energetics compound — there is published human evidence for its effects on energy, focus, and mood at doses used in sports nutrition. The inclusion of theacrine in NAD3 is based on pre-clinical evidence suggesting it may modulate pathways relevant to NAD+ metabolism and aging biology. Whether theacrine's contribution to NAD3's observed lipid and NAD+/NADH effects is pharmacologically separable from the wasabi and copper-niacin components has not been tested in a human trial.

Isothiocyanates from wasabi have been studied in the context of cellular stress responses and Nrf2 pathway activation. The copper(I)-niacin chelate provides bioavailable copper and a form of niacin. Together, the combination is designed to target what the manufacturers describe as the upstream regulation of NAD+ homeostasis rather than its direct synthesis — a plausible mechanism, though one that requires more human validation.

What human studies actually show

The ENHANCE Trial (Roberts et al., 2022) is the only published human RCT on NAD3 as of mid-2026. The trial was a randomized, double-blind, placebo-controlled parallel-group study conducted in 28 middle-aged adults (12 male, 16 female; mean age ~52 years; BMI ~29 kg/m²). Participants received either NAD3 (n = 13; 312 mg/day of the combined Wasabia japonica, theacrine, and copper(I)-niacin blend) or a cellulose placebo (n = 15) for 12 weeks. Blood samples were collected after an overnight fast at baseline and at 12 weeks. (Roberts MD et al., Physiologia, 2022;2(1):20–31. doi: 10.3390/physiologia2010002.)

The primary findings were notable. The NAD3 group showed significant decreases in serum total cholesterol (approximately -11%), LDL cholesterol (approximately -15%), and LDL:HDL ratio (approximately -19%) compared to the placebo group over 12 weeks. A significant interaction was also observed for the cellular NAD+/NADH ratio in peripheral blood mononuclear cells (PBMCs): values at 12 weeks were greater in the NAD3 group than control (p = 0.023), while the control group showed a trend toward declining NAD+/NADH ratio over the same period. No significant differences were found in blood pressure, body mass, or clinical safety markers.

The honest limitation: This is a single small trial (n = 28) funded by JUVN3 Holdings, the ingredient's developer. Twenty-eight participants is an underpowered sample for detecting effects in all intended endpoints, and the study was described by the authors as a subset analysis of a larger ENHANCE Trial, raising questions about selective reporting. No independent replication of these findings has been published as of this writing. The researchers appropriately noted that "the latter data are limited to targeted NAD+ metabolites, and the effects of supplementation on other cellular metabolites or mechanisms related to the observed outcomes need to be further explored." A second ENHANCE Trial publication focused on cellular aging markers at the molecular level was reported by NutraIngredients-USA in May 2023, led by the same Auburn University team, but that work focuses on mechanistic endpoints rather than the clinical outcomes most relevant to supplement users.

NAD3 vs. NMN vs. NR: how do they compare?

These are not equivalent categories. NMN and NR are NAD+ precursors with multiple independent human RCTs demonstrating their ability to raise blood and cellular NAD+ levels; the question for those compounds is which downstream clinical outcomes follow from higher NAD+. NAD3 has a single small industry-funded trial showing a change in the NAD+/NADH ratio (not absolute NAD+) and favorable lipid changes — a different endpoint profile. None of these ingredients have long-term (multi-year) human safety or efficacy data. Our article comparing NR vs. NMN vs. NAD+ covers the precursor comparison in more depth.

The manufacturer's own framing positions NAD3 as a companion to NMN or NR rather than a replacement — which is an honest acknowledgment that the ingredient targets a different biological lever. Whether using both together produces additive benefits has not been tested in humans.

What NAD3 won't do

One published trial in 28 people is not sufficient evidence to make confident recommendations about any ingredient. The favorable lipid findings in the ENHANCE Trial are intriguing — reductions of 11–19% in cholesterol markers over 12 weeks would be clinically meaningful if replicated in larger independent trials, but at this sample size they require confirmation before they can drive purchase decisions. The NAD+/NADH ratio improvement is a mechanistic marker, not a clinical outcome; it suggests the ingredient is biologically active, but the downstream effects on energy, aging biology, or long-term health have not been established in humans.

If you are taking NAD3 because of Sinclair-associated marketing or because you encountered it listed alongside NMN and NR in supplement comparisons, be clear on what it is: a different mechanism, much earlier evidence stage, and a narrower evidence profile than either NMN or NR. It is not necessarily worse — it may address something neither precursor directly targets — but the evidence base is simply too thin to draw strong conclusions either way. As with all supplements, discuss it with a healthcare provider if you have lipid-related concerns or are on lipid-lowering medication, since the observed cholesterol effects would interact with those treatments.

Frequently asked questions

Is NAD3 the same as NAD+?
No. NAD3 is the name of a trademarked nutraceutical ingredient. NAD+ is the molecule that supplement ingredients like NMN, NR, and NAD3 are designed to support. They are entirely different things — the naming overlap causes considerable confusion in search results.

Does NAD3 increase NAD+ levels?
The published trial found a favorable change in the cellular NAD+/NADH ratio in immune cells, but did not find a statistically significant increase in absolute NAD+ concentrations. This is a meaningful distinction. The NAD+/NADH ratio reflects redox balance within cells, and improving it could be biologically relevant even without increasing total NAD+; but this interpretation requires replication in larger trials before it can be accepted with confidence.

Where can I buy NAD3?
NAD3 is a branded ingredient distributed by Compound Solutions and incorporated into various supplement products by brands that license it. It is not a standalone supplement you can buy directly from the ingredient maker. Look for supplement products that specifically list NAD3® as an ingredient on the label.

Is NAD3 safe?
The published trial reported no adverse effects in clinical safety markers over 12 weeks at 312 mg/day. Each ingredient component (theacrine, isothiocyanates from wasabi, copper/niacin) has individual safety records in the literature. However, long-term human safety data specific to the NAD3 combination is not yet published. This is an early-stage ingredient.

How does NAD3 compare to NMN supplements?
NMN has more independent human trials (multiple RCTs with up to 900 mg/day for up to 60 days) and a more robust safety record in humans. NAD3 has a single manufacturer-funded trial. They target different mechanisms. If your primary goal is raising NAD+ levels as measured in blood tests, NMN and NR have stronger and more independent evidence for that specific outcome. For more on NMN's evidence profile, see our article on Nicotinamide Mononucleotide.

The bottom line

NAD3 is a mechanistically interesting ingredient that works through a different pathway than the NAD+ precursors most people have heard of. Its single published human trial showed promising lipid and cellular NAD+/NADH ratio effects in 28 middle-aged adults over 12 weeks. That is a genuinely encouraging start — especially the cholesterol findings, which, if replicated, would be clinically meaningful. But "encouraging start" and "evidence-based recommendation" are not the same thing. NAD3 needs independent replication in larger trials before it earns a strong position alongside NMN and NR, which have substantially deeper human evidence bases. Watch this ingredient: the research program appears active, and the mechanism is logical. Just go in with honest expectations about where the evidence currently sits.

---

References

1. Roberts MD, Osburn SC, Godwin JS, Ruple BA, La Monica MB, Raub B, Sandrock JE, Ziegenfuss TN, Lopez HL. Enhance Trial: Effects of NAD3® on Hallmarks of Aging and Clinical Endpoints of Health in Middle Aged Adults: A Subset Analysis Focused on Blood Cell NAD+ Concentrations and Lipid Metabolism. Physiologia. 2022;2(1):20–31. doi: 10.3390/physiologia2010002.
2. Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2022. doi: 10.1007/s11357-022-00705-1. PMID: 36482258.
3. Dellinger RW, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. npj Aging Mech Dis. 2017;3:17. doi: 10.1038/s41514-017-0016-9.
4. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. J Gerontol A Biol Sci Med Sci. 2023;78(12):2435–2448. doi: 10.1093/gerona/glad106. PMID: 37068054; PMCID: PMC10692436.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.